Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33991 | 0.78 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5653344 | 0.76 | SIGMAR1 (0.50) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL3681409 | 0.74 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL15848206 | 0.72 | EPHX1 (0.44) | SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL20061130 | 0.69 | SIGMAR1 (0.56) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL20061148 | 0.69 | SIGMAR1 (0.56) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL5807375 | 0.69 | SIGMAR1 (0.35) | SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL17479478 | 0.67 | SIGMAR1 (0.50) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL2799200 | 0.67 | EPHX1 (0.42) | SIGMAR1TAAR1CYP2D6 | |
| SCHEMBL21243273 | 0.66 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346788-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | Arcadia Medicine, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20230201160-A1 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS | UNIVERSITATSSPITAL BASEL (CH) | 2023-06-29 | — | — | US | claimed |
| CN-115811975-A | MDMA treatment to enhance the acute emotional response characteristics of LSD, siloxibin, or other hallucinogens | 巴塞尔大学医院 | 2023-03-17 | — | — | CN | claimed |
| EP-4138815-A1 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS | Universitätsspital Basel (CH) | 2023-03-01 | — | — | EP | claimed |
| WO-2022256720-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | ARCADIA MEDICINE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| US-11364221-B2 | MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics | UNIVERSITÄTSSPITAL BASEL (CH) | 2022-06-21 | — | — | US | claimed |
| US-20220096429-A1 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS | UNIVERSITÄTSSPITAL BASEL (CH) | 2022-03-31 | — | — | US | claimed |
| WO-2021225796-A1 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS | UNIVERSITÄTSSPITAL BASEL (CH) | 2021-11-11 | — | — | WO | claimed |
| US-20120108510-A1 | METHODS OF IMPROVING BEHAVIORAL THERAPIES | EMORY UNIVERSITY (US) | 2012-05-03 | — | — | US | claimed |
| EP-1501352-A4 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE OF DRUGS | UNIV WYOMING (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005039381-A2 | COMPOSITIONS AND PROCESSES FOR ANALYSIS OF PHARMACOLOGIC AGENTS IN BIOLOGICAL SAMPLES | DRUG RISK SOLUTIONS, L.L.C. (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050037386-A1 | Composition and processes for analysis of pharmacologic agents in biological samples | DRUG RISK SOLUTIONS, L.L.C. | 2005-02-17 | — | — | US | claimed |
| EP-1501352-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE OF DRUGS | THE UNIVERSITY OF WYOMING (US) | 2005-02-02 | — | — | EP | claimed |
| US-20050002895-A1 | Methods and compositions for controlled release of drugs | WYOMING, UNIVERSITY OF, THE | 2005-01-06 | — | — | US | claimed |
| WO-2003051113-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE OF DRUGS | THE UNIVERSITY OF WYOMING (US) | 2003-06-26 | — | — | WO | claimed |
| EP-4687880-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-1196784-A2 | PROCESS FOR THE QUANTITATIVE DETERMINATION OF ALKALOIDS SUCH AS COCAINE IN A SOLID SAMPLE AND REAGENT FOR USE IN SUCH PROCESS | Azienda Provinciale Per I Servizi Sanitari (IT) | 2002-04-17 | — | — | EP | disclosed |
| EP-1167976-A2 | Immunoassay for the detection of amphetamines and derivatives thereof | BOEHRINGER MANNHEIM GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001006251-A2 | PROCESS FOR THE QUANTITATIVE DETERMINATION OF ALKALOIDS SUCH AS COCAINE IN A SOLID SAMPLE AND REAGENT FOR USE IN SUCH PROCESS | AZIENDA PROVINCIALE PER I SERVIZI SANITARI (IT) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050002895-A1 | Methods and compositions for controlled release of drugs | OPRK1, OPRM1, OPRL1 | SIGMAR1 6/4885TAAR1 50/4885SLC18A2 95/4885 |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | HCN1, HCN4, CRH | SIGMAR1 821/4885TAAR1 425/4885SLC18A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.